Pharmaceuticals (Dec 2022)

Prevalence of Diabetes and Its Association with Atherosclerotic Cardiovascular Disease Risk in Patients with Familial Hypercholesterolemia: An Analysis from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)

  • Chrysoula Boutari,
  • Christos V. Rizos,
  • Michalis Doumas,
  • George Liamis,
  • Ioannis Skoumas,
  • Loukianos Rallidis,
  • Anastasia Garoufi,
  • Genovefa Kolovou,
  • Konstantinos Tziomalos,
  • Emmanouil Skalidis,
  • Vasileios Kotsis,
  • George Sfikas,
  • Vaia Lambadiari,
  • Panagiotis Anagnostis,
  • Eleni Bilianou,
  • Georgia Anastasiou,
  • Iosif Koutagiar,
  • Estela Kiouri,
  • Achilleas Attilakos,
  • Vana Kolovou,
  • Evangelos Zacharis,
  • Christina Antza,
  • Evangelos Liberopoulos

DOI
https://doi.org/10.3390/ph16010044
Journal volume & issue
Vol. 16, no. 1
p. 44

Abstract

Read online

Familial hypercholesterolemia (FH) and type 2 diabetes mellitus (T2DM) are both associated with a high risk of atherosclerotic cardiovascular disease (ASCVD). Little is known about the prevalence of T2DM and its association with ASCVD risk in FH patients. This was a cross-sectional analysis from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH) including adults with FH (n = 1719, mean age 51.3 ± 14.6 years). Of FH patients, 7.2% had a diagnosis of T2DM. The prevalence of ASCVD, coronary artery disease (CAD), and stroke was higher among subjects with T2DM compared with those without (55.3% vs. 23.3%, 48.8% vs. 20.7%, 8.3% vs. 2.7%, respectively, p p = 0.004]. FH patients with T2DM were more likely to have undergone coronary revascularization than those without (14.2% vs. 4.5% for coronary artery bypass graft, and 23.9% vs. 11.5% for percutaneous coronary intervention, p < 0.001). T2DM is associated with an increased risk for prevalent ASCVD in subjects with FH. This may have implications for risk stratification and treatment intensity in these patients.

Keywords